ABCAM Plc ABC Director/PDMR Shareholding

  ABCAM Plc (ABC) - Director/PDMR Shareholding

RNS Number : 7551P
ABCAM Plc
29 October 2012




For immediate release 29 October 2012

                                      

                                  ABCAM PLC

                          ("Abcam" or "the Company")

                 Director/PDMR dealing: Share Incentive Plan

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein
research tools, has today been notified of the following transactions under
the Abcam plc Share Incentive Plan to the benefit of the Executive Directors
and PDMRs in line with the regular annual invitation to participate:

           Name        Partnership Shares      Matching Shares Free Shares
                       purchased on 26 October granted on 26   awarded on 26
                       2012 at 381p per 0.2    October 2012 at October 2012 at
                       pence Ordinary Share    381p per 0.2   381p per 0.2
                                               pence Ordinary  pence Ordinary
                                               Share           Share
Executive  Jonathan                        393             393             787
Directors: Milner
           Jim Warwick                     393             393             787
           Jeff Iliffe                     393             393             787
PDMRs:     Mark                            394             394             787
           Bushfield
           Jane Cooke                      394             394             787
           Philippe                        394             394             787
           Cotrel
           Ed Ralph                        393             393             787



The risk of forfeiture attached to the Matching Shares will normally be
removed on the third anniversary of the award subject to continued employment
and the retention of the Partnership Shares in connection with which they were
awarded. The risk of forfeiture attached to the Free Shares will normally be
removed on the third anniversary of the award subject to continued employment.

No consideration was paid by the above grantees for the award of the Matching
and Free Shares and no consideration is due on the release of these shares.



For further information please contact:

Abcam                                               + 44 (0) 1223 696 000
Jeff Iliffe, Chief Financial Officer


Numis Securities - Nominated Adviser & Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking


Peel Hunt LLP - Joint Broker                        + 44 (0) 20 7418 8900
Andy Crossley - Corporate Broking


Buchanan                                            + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles



Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools.
These tools enable life scientists to analyse components of living cells at
the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK),
Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan),
Hangzhou and Hong Kong (both in China), allowing it to serve a global customer
base in over 130 countries. Abcam employs over 600 staff across its eight
operating companies.

Abcam now has an online catalogue of over 98,500 products sourced from over
400 suppliers. The catalogue includes a growing range of non-primary antibody
products such as secondaries, proteins, peptides, lysates, immunoassays and
other kits. Products are available for life science research and distributed
to academic and commercial users. A highly developed eCommerce platform, which
includes regional websites for the Chinese and Japanese markets, allows
customers to access up-to-date and detailed technical product data sheets at
the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol
ABC. The Company's vision is to be the world's leading life science reagents
company.

                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


RDSLKLFLLBFBFBF -0- Oct/29/2012 12:01 GMT
 
Press spacebar to pause and continue. Press esc to stop.